RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Threat attack on blood cancer tested in patients
Disease control OngoingThis study is testing whether a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—can control the growth of chronic lymphocytic leukemia (CLL). It is enrolling adults with CLL, including those whose cancer has come back after treatment and those who have never…
Matched conditions: RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for patients Who've run out of options: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…
Matched conditions: RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control OngoingThis study is testing an experimental drug called BGB-11417 in adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to standard treatments. The trial aims to see how well the drug controls the cancer and how safe it is for pat…
Matched conditions: RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC